5 recruiting, 2 active not recruiting, 2 completed, 2 withdrawn. 8 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 3, Active not recruiting 2, Completed 2, Not yet recruiting 1 |
| Phase 2 | 8 | Recruiting 3, Withdrawn 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow KRAS G12C: new trials by email Literature Review of KRAS G12C trials Research Report on KRAS G12C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC Glecirasib, Ivonescimab - NSCLC Stage IV, KRAS G12C | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 42 | 2026-03-01 | 2026-01-14 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC Sotorasib, Lenvatinib - Metastatic Non Small Cell Lung Cancer, KRAS G12C | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2025-03-01 | 2024-11-20 | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases Adagrasib, Stereotactic Radiosurgery - Non Small Cell Lung Cancer, NSCLC | Phase 2 | Recruiting | Ryan Gentzler, MD | 30 | 2024-08-06 | 2026-04-08 |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer BBO-8520, Pembrolizumab, BBO-10203 - Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 350 | 2024-05-22 | 2026-09-03 |
| JDQ443 for KRAS G12C NSCLC Brain Metastases JDQ443 - Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult | Phase 2 | Withdrawn | Maastricht University Medical Center | 2024-04-15 | 2024-05-29 | |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors FMC-376 - Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Frontier Medicines Corporation | 293 | 2024-02-12 | 2026-10-19 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors TT125-802 - Advanced Solid Tumor, Adult Solid Tumor | Phase 1 | Completed | TOLREMO therapeutics AG | 45 | 2023-11-07 | 2026-07-07 |
| A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors ELI-002 7P - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Elicio Therapeutics | 158 | 2023-04-14 | 2026-07-10 |
| CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide - Solid Tumor, Adult, EphA2 Overexpression | Phase 1 | Active not recruiting | Chinese PLA General Hospital | 9 | 2023-04-03 | 2025-11-24 |
| A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations GFH925 - KRAS G12C | Phase 1 / Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 334 | 2021-09-13 | 2025-11-17 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma ELI-002 7P - Pancreatic Ductal Adenocarcinoma, KRAS G12D | No longer available | Elicio Therapeutics | 2026-07-10 |
Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (3) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Arteriovenous Malformations (1) · Brain Neoplasms (1) · Colonic Neoplasms (1) · Disease (1) · Lymphangioma (1) · Lymphangioma, Cystic (1) · Lymphatic Abnormalities (1) · Neoplasms (1) · Rectal Neoplasms (1) · Skin Diseases, Vascular (1) · Vascular Malformations (1)
Neoplasms (10) · Neoplasms by Site (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Lung Neoplasms (5) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Neoplastic Processes (3) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Cyclophosphamide (1) · Gemcitabine (1) · Injections (1) · Ipilimumab (1) · JDQ443 (1) · Pemetrexed (1) · Radiosurgery (1) · adagrasib (1)
Elicio Therapeutics (2) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · ETOP IBCSG Partners Foundation (1) · Frontier Medicines Corporation (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Maastricht University Medical Center (1) · Murdoch Childrens Research Institute (1) · Ryan Gentzler, MD (1) · TOLREMO therapeutics AG (1)
United States (6) · Australia (4) · Spain (3) · China (2) · Switzerland (2) · Austria (1) · Canada (1) · Denmark (1) · Germany (1) · South Korea (1)
Alfredo Addeo (1) · Lizza Hendriks, MD, PhD (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Ryan Gentzler, MD, MS (1) · Sanjay Popat (1) · Stephen Luen, MBChB, FRACP. (1) · Tony Penington, MBBS, FRACS. (1) · Yang Xu, Ph.D (1)
PMID 39127176, PMID 40715048, PMID 41790032
2023 (1)